Investigational antiviral therapies for the treatment of influenza

References

• Dawood FS, Iuliano AD, Reed C, et al. Estimated global mortality associated with the first 12 months of 2009 pandemic influenza A H1N1 virus circulation: a modelling study. Lancet Infect Dis. 2012;12:687–695.
   PubMed Web of Science ®Google Scholar
• Hatta M, Gao P, Halfmann P, et al. Molecular basis for high virulence of Hong Kong H5N1 influenza A viruses. Science. 2001;293:1840–1842.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zhang Q, Kong H, et al. H5N1 hybrid viruses bearing 2009/H1N1 virus genes transmit in guinea pigs by respiratory droplet. Science. 2013;340:1459–1463.
   PubMed Web of Science ®Google Scholar
• Gao R, Cao B, Hu Y, et al. Human infection with a novel avian-origin influenza A (H7N9) virus. N Engl J Med. 2013;368:1888–1897.
   PubMed Web of Science ®Google Scholar
• Treanor JJ. Prospects for broadly protective influenza vaccines. Am J Prev Med. 2015;33:D39–D45.
   Google Scholar
• Beard KR, Brendish NJ, Clark TW. Treatment of influenza with neuraminidase inhibitors. Curr Opin Infect Dis. 2018;31:514–519.
   PubMed Web of Science ®Google Scholar
• Dong GY, Peng C, Luo J, et al. Adamantane-resistant influenza A viruses in the World (1902–2013): frequency and distribution of M2 gene mutations. Plos One. 2015;10:20.
   Web of Science ®Google Scholar
• Lackenby A, Besselaar TG, Daniels RS, et al. Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors and status of novel antivirals, 2016–2017. Antiviral Res. 2018;157:38–46.
   PubMed Web of Science ®Google Scholar
• Lee N, Hurt AC. Neuraminidase inhibitor resistance in influenza: a clinical perspective. Curr Opin Infect Dis. 2018;31:520–526.
   PubMed Web of Science ®Google Scholar
• Hussain M, Galvin HD, Haw TY, et al. Drug resistance in influenza A virus: the epidemiology and management. Infect Drug Resist. 2017;10:121–134.
   PubMed Web of Science ®Google Scholar
• Te AJW, Fodor E. Influenza virus RNA polymerase: insights into the mechanisms of viral RNA synthesis. Nat Rev Microbiol. 2016;14:479–493.
   Web of Science ®Google Scholar
• Stevaert A, Naesens L. The influenza virus polymerase complex: an update on its structure, functions, and significance for antiviral drug design. Med Res Rev. 2016;36:1127–1173.
   PubMed Web of Science ®Google Scholar
• Lo CY, Tang YS, Shaw PC. Structure and function of influenza virus ribonucleoprotein. Subcell Biochem. 2018;88:95–128.
   PubMedGoogle Scholar
• Zhou ZX, Liu T, Zhang J, et al. Influenza A virus polymerase: an attractive target for next-generation anti-influenza therapeutics. Drug Discov Today. 2018;23:503–508.
   PubMed Web of Science ®Google Scholar
• Giese S, Ciminski K, Bolte H, et al. Role of influenza A virus NP acetylation on viral growth and replication. Nat Commun. 2017;8:1259.
   PubMed Web of Science ®Google Scholar
• Massari S, Goracci L, Desantis J, et al. Polymerase acidic protein-basic protein 1 (PA-PB1) protein-protein interaction as a target for next-generation anti-influenza therapeutics. J Med Chem. 2016;59:7699–7718.
   PubMed Web of Science ®Google Scholar
• Watanabe K, Ishikawa T, Otaki H, et al. Structure-based drug discovery for combating influenza virus by targeting the PA-PB1 interaction. Sci Rep. 2017;7:9500.
   PubMed Web of Science ®Google Scholar
• Severin C, Rocha DMT, Liu Y, et al. The cap-binding site of influenza virus protein PB2 as a drug target. Acta Crystallogr D Struct Biol. 2016;72:245–253.
   PubMedGoogle Scholar
• Chenavas S, Crépin T, Delmas B, et al. Influenza virus nucleoprotein: structure, RNA binding, oligomerization and antiviral drug target. Future Microbiol. 2013;8:1537–1545.
   PubMed Web of Science ®Google Scholar
• Maki K, Kazumi T, Yuko ST, et al. T-705 (favipiravir) activity against lethal H5N1 influenza A viruses. Proc Natl Acad Sci Usa. 2010;107:882–887.
   PubMed Web of Science ®Google Scholar
• Ma XL, Xie LL, Wartchow C, et al. Structural basis for therapeutic inhibition of influenza A polymerase PB2 subunit. Sci Rep. 2017;7:9385.
   PubMed Web of Science ®Google Scholar
• Long JCD, Fodor E. The PB2 Subunit of the influenza A virus RNA polymerase is imported into the mitochondrial matrix. J Virol. 2016;90:8729–8738.
   Web of Science ®Google Scholar
• Graef KM, Vreede FT, Lau YF, et al. The PB2 subunit of the influenza virus RNA polymerase affects virulence by interacting with the mitochondrial antiviral signaling protein and inhibiting expression of beta interferon. J Virol. 2010;84:8433–8445.
   PubMed Web of Science ®Google Scholar
• Liu T, Liu M, Chen F, et al. A small-molecule compound has anti-influenza A virus activity by acting as a “PB2 inhibitor”. Mol Pharm. 2018;15:4110–4120.
   PubMed Web of Science ®Google Scholar
• Xiong J, Wang J, Hu G, et al. Design, synthesis and biological evaluation of novel, orally bioavailable pyrimidine-fused heterocycles as influenza PB2 inhibitors. Eur J Med Chem. 2018;162:249–265.
   PubMed Web of Science ®Google Scholar
• Yuan S, Chu H, Zhang K, et al. A novel small-molecule compound disrupts influenza A virus PB2 cap-binding and inhibits viral replication. J Antimicrob Chemother. 2016;71:2489–2497.
   PubMed Web of Science ®Google Scholar
• Wang J, Chen F, Liu Y, et al. Spirostaphylotrichin X from a marine-derived fungus as an anti-influenza agent targeting RNA polymerase PB2. J Nat Prod. 2018.
   Web of Science ®Google Scholar
• Luo X, Yang J, Chen F, et al. Structurally diverse polyketides from the mangrove-derived fungus diaporthe sp. Front Chem. 2018;6:282.
   PubMed Web of Science ®Google Scholar
• CC-42344. Available from: https://www.cocrystalpharma.com/development-pipeline/influenza/cc-42344
   Google Scholar
• Byrn RA, Jones SM, Bennett HB, et al. Preclinical activity of VX-787, a first-in-class, orally bioavailable inhibitor of the influenza virus polymerase PB2 subunit. Antimicrob Agents Chemother. 2015;59:1569–1582.
   PubMed Web of Science ®Google Scholar
• Clark MP, Ledeboer MW, Davies I, et al. Discovery of a novel, first-in-class, orally bioavailable azaindole inhibitor (VX-787) of influenza PB2. J Med Chem. 2014;57:6668–6678.
   PubMed Web of Science ®Google Scholar
• Fu Y, Gaelings L, Soderholm S, et al. JNJ872 inhibits influenza A virus replication without altering cellular antiviral responses. Antiviral Res. 2016;133:23–31.
   PubMed Web of Science ®Google Scholar
• Deleu S, Kakuda TN, Spittaels K, et al. Single- and multiple-dose pharmacokinetics and safety of pimodivir, a novel, non-nucleoside polymerase basic protein 2 subunit inhibitor of the influenza A virus polymerase complex, and interaction with oseltamivir: a Phase 1 open-label study in healthy volunteers. Br J Clin Pharmacol. 2018;84:2663–2672.
   PubMed Web of Science ®Google Scholar
• Trevejo JM, Asmal M, Vingerhoets J, et al. Pimodivir treatment in adult volunteers experimentally inoculated with live influenza virus: a Phase IIa, randomized, double-blind, placebo-controlled study. Antivir Ther. 2018;23:335–344.
   PubMed Web of Science ®Google Scholar
• Finberg RW, Lanno R, Anderson D, et al. Phase 2b study of pimodivir (JNJ-63623872) as monotherapy or in combination with oseltamivir for treatment of acute uncomplicated seasonal influenza A: TOPAZ trial. J Infect Dis. 2018;219:1026-1034.
   Web of Science ®Google Scholar
• Watanabe K, Ishikawa T, Otaki H. Structure-based drug discovery for combating influenza virus by targeting the PA-PB1 interaction. Sci Rep. 2017;7:12.
   PubMed Web of Science ®Google Scholar
• Obayashi E, Yoshida H, Kawai F, et al. The structural basis for an essential subunit interaction in influenza virus RNA polymerase. Nature. 2008;454:1127–1131.
   PubMed Web of Science ®Google Scholar
• Binh NT, Wakai C, Kawaguchi A, et al. Involvement of the N-terminal portion of influenza virus RNA polymerase subunit PB1 in nucleotide recognition. Biochem Biophys Res Commun. 2014;443:975–979.
   PubMed Web of Science ®Google Scholar
• Massari S, Nannetti G, Desantis J, et al. A broad anti-influenza hybrid small molecule that potently disrupts the interaction of polymerase acidic protein-basic protein 1 (PA-PB1) subunits. J Med Chem. 2015;58:3830–3842.
   PubMed Web of Science ®Google Scholar
• Giulia M, Laura G, Beatrice M, et al. Small molecule inhibitors of influenza A and B viruses that act by disrupting subunit interactions of the viral polymerase. Proc Natl Acad Sci U S A. 2012;109:6247–6252.
   PubMed Web of Science ®Google Scholar
• Tintori C, Laurenzana I, Fallacara AL, et al. High-throughput docking for the identification of new influenza A virus polymerase inhibitors targeting the PA–PB1 protein–protein interaction. Bioorg Med Chem Lett. 2014;24:280–282.
   PubMed Web of Science ®Google Scholar
• Lepri S, Nannetti G, Muratore G, et al. Optimization of small-molecule inhibitors of influenza virus polymerase: from thiophene-3-carboxamide to polyamido scaffolds. J Med Chem. 2014;57:4337–4350.
   PubMed Web of Science ®Google Scholar
• D‘Agostino I, Giacchello I, Nannetti G, et al. Synthesis and biological evaluation of a library of hybrid derivatives as inhibitors of influenza virus PA-PB1 interaction. Eur J Med Chem. 2018;157:743–758.
   PubMed Web of Science ®Google Scholar
• Trist IM, Nannetti G, Tintori C, et al. 4,6-Diphenylpyridines as promising novel anti-influenza agents targeting the PA-PB1 protein-protein interaction: structure-activity relationships exploration with the aid of molecular modeling. J Med Chem. 2016;59:2688–2703.
   PubMed Web of Science ®Google Scholar
• Ortigoza MB, Dibben O, Maamary J, et al. A novel small molecule inhibitor of influenza A viruses that targets polymerase function and indirectly induces interferon. Plos Pathog. 2012;8:e1002668.
   PubMed Web of Science ®Google Scholar
• Lou Z, Sun Y, Rao Z. Current progress in antiviral strategies. Trends Pharmacol Sci. 2014;35:86–102.
   PubMed Web of Science ®Google Scholar
• Yuan S, Chu H, Ye J, et al. Identification of a novel small-molecule compound targeting the influenza A virus polymerase PB1-PB2 interface. Antiviral Res. 2017;137:58–66.
   PubMed Web of Science ®Google Scholar
• Matusevich OV, Egorov VV, Gluzdikov IA, et al. Synthesis and antiviral activity of PB1 component of the influenza A RNA polymerase peptide fragments. Antiviral Res. 2015;113:4–10.
   PubMed Web of Science ®Google Scholar
• Wunderlich K, Juozapaitis M, Ranadheera C, et al. Identification of high-affinity PB1-derived peptides with enhanced affinity to the PA protein of influenza A virus polymerase. Antimicrob Agents Chemother. 2011;55:696–702.
   PubMed Web of Science ®Google Scholar
• Ghanem A, Mayer D, Chase G, et al. Peptide-mediated interference with influenza A virus polymerase. J Virol. 2007;81:7801–7804.
   PubMed Web of Science ®Google Scholar
• Yuan P, Bartlam M, Lou Z, et al. Crystal structure of an avian influenza polymerase PA(N) reveals an endonuclease active site. Nature. 2009;458:909–913.
   PubMed Web of Science ®Google Scholar
• Pala N, Stevaert A, Dallocchio R, et al. Virtual screening and biological validation of novel influenza virus PA endonuclease inhibitors. ACS Med Chem Lett. 2015;6:866–871.
   PubMed Web of Science ®Google Scholar
• Datta K, Wolkerstorfer A, Szolar OH, et al. Characterization of PA-N terminal domain of Influenza A polymerase reveals sequence specific RNA cleavage. Nucleic Acids Res. 2013;41:8289–8299.
   PubMed Web of Science ®Google Scholar
• Ju H, Zhang J, Huang B, et al. Inhibitors of influenza virus polymerase acidic (PA) endonuclease: contemporary developments and perspectives. J Med Chem. 2017;60:3533–3551.
   PubMed Web of Science ®Google Scholar
• Yuan S, Chu H, Singh K, et al. A novel small-molecule inhibitor of influenza A virus acts by suppressing PA endonuclease activity of the viral polymerase. Sci Rep. 2016;6:22880.
   PubMed Web of Science ®Google Scholar
• Wunderlich K, Mayer D, Ranadheera C, et al. Identification of a PA-binding peptide with inhibitory activity against influenza A and B virus replication. Plos One. 2009;4:e7517.
   PubMed Web of Science ®Google Scholar
• Bauman JD, Patel D, Baker SF, et al. Crystallographic fragment screening and structure-based optimization yields a new class of influenza endonuclease inhibitors. Acs Chem Biol. 2013;8:2501–2508.
   PubMed Web of Science ®Google Scholar
• Baughman BM, Jake SP, DuBois RM, et al. Identification of influenza endonuclease inhibitors using a novel fluorescence polarization assay. Acs Chem Biol. 2012;7:526–534.
   PubMed Web of Science ®Google Scholar
• Jones JC, Marathe BM, Lerner C, et al. A novel endonuclease inhibitor exhibits broad-spectrum anti-influenza virus activity in vitro. Antimicrob Agents Ch. 2016;60:5504.
   PubMed Web of Science ®Google Scholar
• Credille CV, Chen Y, Cohen SM. Fragment-based identification of influenza endonuclease inhibitors. J Med Chem. 2016;59:6444–6454.
   PubMed Web of Science ®Google Scholar
• Kakuda TN, Yogaratnam J, Rito J, et al. Phase I study on safety and pharmacokinetics of a novel influenza endonuclease inhibitor, AL-794 (JNJ-64155806), following single- and multiple-ascending doses in healthy adults. Antivir Ther. 2018;23:555-566.
   PubMed Web of Science ®Google Scholar
• Yogaratnam J, Rito J, Kakuda TN, et al. Antiviral activity, safety, and pharmacokinetics of AL-794, a novel oral influenza endonuclease inhibitor: results of an influenza human challenge study. J Infect Dis. 2018;219:177-185.
   Web of Science ®Google Scholar
• Kikuchi T, Watanabe A. Baloxavir heralds a new era in influenza virus biology. Respir Investig. 2018;57:1-2.
   Web of Science ®Google Scholar
• Noshi T, Kitano M, Taniguchi K, et al. In vitro characterization of baloxavir acid, a first-in-class cap-dependent endonuclease inhibitor of the influenza virus polymerase PA subunit. Antiviral Res. 2018;160:109–117.
   PubMed Web of Science ®Google Scholar
• Hayden FG, Sugaya N, Hirotsu N, et al. Baloxavir marboxil for uncomplicated influenza in adults and adolescents. N Engl J Med. 2018;379:913–923.
   PubMed Web of Science ®Google Scholar
• Yang TR. Baloxavir marboxil: the first cap-dependent endonuclease inhibitor for the treatment of influenza. Ann Pharmacother. 2019.
   Web of Science ®Google Scholar
• Koshimichi H, Ishibashi T, Kawaguchi N, et al. Safety, tolerability, and pharmacokinetics of the novel anti-influenza agent baloxavir marboxil in healthy adults: phase I study findings. Clin Drug Investig. 2018;38:1189–1196.
   PubMed Web of Science ®Google Scholar
• Omoto S, Speranzini V, Hashimoto T, et al. Characterization of influenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil. Sci Rep. 2018;8:9633.
   PubMed Web of Science ®Google Scholar
• Fukao K, Noshi T, Yamamoto A, et al. Combination treatment with the cap-dependent endonuclease inhibitor baloxavir marboxil and a neuraminidase inhibitor in a mouse model of influenza A virus infection. J Antimicrob Chemoth. 2018;74:654-662.
   Web of Science ®Google Scholar
• Kumar G, White SW. Identification of the I38T PA substitution as a resistance marker for next-generation influenza virus endonuclease inhibitors. Mbio. 2018;9:e418–e430.
   Web of Science ®Google Scholar
• Davis AM, Ramirez J, Newcomb LL. Identification of influenza A nucleoprotein body domain residues essential for viral RNA expression expose antiviral target. Virol J. 2017;14:13.
   PubMed Web of Science ®Google Scholar
• Hayden FG, Sugaya N, Hirotsu N, et al. Baloxavir marboxil for uncomplicated influenza in adults and adolescents. N Engl J Med. 2018;379:913–923.
   PubMed Web of Science ®Google Scholar
• Kao RY, Yang D, Lau LS, et al. Identification of influenza A nucleoprotein as an antiviral target. Nat Biotechnol. 2010;28:600–605.
   PubMed Web of Science ®Google Scholar
• Arranz R, Coloma R, Chichon FJ, et al. The structure of native influenza virion ribonucleoproteins. Science. 2012;338:1634–1637.
   PubMed Web of Science ®Google Scholar
• Lin MI, Su BH, Lee CH, et al. Synthesis and inhibitory effects of novel pyrimido-pyrrolo-quinoxalinedione analogues targeting nucleoproteins of influenza A virus H1N1. Eur J Med Chem. 2015;102:477–486.
   PubMed Web of Science ®Google Scholar
• Cheng H, Wan J, Lin MI, et al. Design, synthesis, and in vitro biological evaluation of 1H-1,2,3-triazole-4-carboxamide derivatives as new anti-influenza A agents targeting virus nucleoprotein. J Med Chem. 2012;55:2144–2153.
   PubMed Web of Science ®Google Scholar
• Hagiwara K, Kondoh Y, Ueda A, et al. Discovery of novel antiviral agents directed against the influenza A virus nucleoprotein using photo-cross-linked chemical arrays. Biochem Biophys Res Commun. 2010;394:721–727.
   PubMed Web of Science ®Google Scholar
• Pang B, Cheung NN, Zhang W, et al. Structural characterization of h1n1 nucleoprotein-nucleozin binding sites. Sci Rep. 2016;6:29684.
   PubMed Web of Science ®Google Scholar
• Lejal N, Tarus B, Bouguyon E, et al. Structure-based discovery of the novel antiviral properties of naproxen against the nucleoprotein of influenza A virus. Antimicrob Agents Chemother. 2013;57:2231–2242.
   PubMed Web of Science ®Google Scholar
• Tarus B, Bertrand H, Zedda G, et al. Structure-based design of novel naproxen derivatives targeting monomeric nucleoprotein of influenza A virus. J Biomol Struct Dyn. 2015;33:1899–1912.
   PubMed Web of Science ®Google Scholar
• Zhang X, Zhan G, Jin M, et al. Botany, traditional use, phytochemistry, pharmacology, quality control, and authentication of Radix gentianae macrophyllae -A traditional medicine: A review. Phytomedicine. 2018;46:142-163.
   Web of Science ®Google Scholar
• Wen H, Han H, Wei W, et al. Anti-influenza virus effect of aqueous extracts from dandelion. Virol J. 2011;8:538.
   PubMed Web of Science ®Google Scholar
• Theisen LL, Muller CP. EPs®; 7630 (Umckaloabo®;), an extract from Pelargonium sidoides roots, exerts anti-influenza virus activity in vitro and in vivo. Antivir Res. 2012;94:147–156.
   PubMed Web of Science ®Google Scholar
• Zhang T, Xiao M, Wong CK, et al. Sheng Jiang San, a traditional multi-herb formulation, exerts anti-influenza effects in vitro and in vivo via neuraminidase inhibition and immune regulation. BMC Complement Altern Med. 2018;18:150.
   PubMed Web of Science ®Google Scholar
• Jin YH, Choi JG, Cho WK, et al. Ethanolic extract of melia fructus has anti-influenza a virus activity by affecting viral entry and viral RNA polymerase. Front Microbiol. 2017;8:476.
   PubMed Web of Science ®Google Scholar
• Hyuga S, Hyuga M, Oshima N, et al. Ephedrine alkaloids-free ephedra herb extract: a safer alternative to ephedra with comparable analgesic, anticancer, and anti-influenza activities. J Nat Med. 2016;70:571–583.
   PubMed Web of Science ®Google Scholar
• Zeng LY, Yang J, Liu S. Investigational hemagglutinin-targeted influenza virus inhibitors. Expert Opin Investig Drugs. 2017;26:63–73.
   PubMed Web of Science ®Google Scholar
• Rossignol JF. Nitazoxanide: A first-in-class broad-spectrum antiviral agent. Antiviral Res. 2014;110:94–103.
   PubMed Web of Science ®Google Scholar
• Haffizulla J, Hartman A, Hoppers M, et al. Effect of nitazoxanide in adults and adolescents with acute uncomplicated influenza: a double-blind, randomised, placebo-controlled, phase 2b/3 trial. Lancet Infect Dis. 2014;14:609–18.89.
   PubMed Web of Science ®Google Scholar
• Tilmanisa D, van Baalen C, Dy O, et al. The susceptibility of circulating human influenza viruses to tizoxanide, the active metabolite of nitazoxanide. Antiviral Res. 2017;147:142–148.
   PubMed Web of Science ®Google Scholar
• Belardo G, Cenciarelli O, La Frazia S, et al. Synergistic effect of nitazoxanide with neuraminidase inhibitors against influenza A viruses in vitro. Antimicrob Agents Chemother. 2015;59:1061–1069.
   PubMed Web of Science ®Google Scholar
• Nitazoxanide. Available from: https://clinicaltrials.gov/ct2/show/NCT01610245.2018.
   Google Scholar
• Marathe BM, Wong SS, Vogel P, et al. Combinations of oseltamivir and T-705 extend the treatment window for highly pathogenic influenza A(H5N1) virus infection in mice. Sci Rep. 2016;6:26742.
   PubMed Web of Science ®Google Scholar
• D‘Elia RV, Harrison K, Oyston PC, et al. Targeting the “cytokine storm” for therapeutic benefit. Clin Vaccine Immunol Cvi. 2013;20:319–327.
   PubMed Web of Science ®Google Scholar
• Wang S, Le TQ, Kurihara N, et al. Influenza virus-cytokine-protease cycle in the pathogenesis of vascular hyperpermeability in severe influenza. J Infect Dis. 2010;202:991–1001.
   PubMed Web of Science ®Google Scholar